XLV - Health Care Select Sector SPDR® Fund

NYSEArca - Nasdaq Real Time Price. Currency in USD
82.54
+0.38 (+0.46%)
As of 9:37AM EDT. Market open.
Stock chart is not supported by your current browser
Previous close82.16
Open82.40
Bid81.33 x 100
Ask82.65 x 5200
Day's range82.40 - 82.64
52-week range74.45 - 91.79
Volume185,586
Avg. volume10,305,512
Net assets15.32B
NAV81.24
PE ratio (TTM)N/A
Yield1.53%
YTD return-1.20%
Beta (3y)0.93
Expense ratio (net)0.14%
Inception date1998-12-16
Trade prices are not sourced from all markets
  • Another Indicator Signaling Rising Inflation
    Market Realist7 days ago

    Another Indicator Signaling Rising Inflation

    The US Bureau of Labor Statistics releases a monthly report that tracks price trends in wholesale markets. Industries from the manufacturing sector (XLI) are surveyed for changes in input prices, and this survey data is used to construct the PPI (Producer Price Index). The survey comprises questions on raw material prices, production levels, and finished goods.

  • 3.2 Million Americans Quit Their Jobs in February
    Market Realist8 days ago

    3.2 Million Americans Quit Their Jobs in February

    The “Job Openings and Labor Turnover Survey” (or JOLTS) data for February was reported on April 13, and it contains information about job openings and total separations. The total number of separations includes layoffs, retirements, and voluntary quitting. As per the latest JOLTS report, the total separations for February was 5.2 million at a rate of 3.5% of the total workforce and a decrease from the January reading of 5.9 million and 4.1%, respectively.

  • What to Expect from Johnson & Johnson’s 1Q18 Earnings
    Market Realist10 days ago

    What to Expect from Johnson & Johnson’s 1Q18 Earnings

    Johnson & Johnson's 1Q18 Earnings: What to Expect on April 17Johnson & Johnson’s estimates

  • Barrons.com13 days ago

    Medical-Device Makers Need Robust Results

    As we approach another earnings season, medical-device companies look poised to report quarters in line with expectations. At least that's the warning from Morgan Stanley's David Lewis. He writes that first-quarter fundamentals look encouraging for the group, given a favorable utilization environment at the start of the year—and a more severe flu season than usual that could serve as another tailwind. Among large-caps in the space, Lewis says Intuitive Surgical (ISRG), Becton Dickinson (BDX), and Zimmer Biomet (ZBH) have a good chance of beating expectations.

  • When US military has attacked in Middle East, it hasn't ended well for oil or energy stocks
    CNBC15 days ago

    When US military has attacked in Middle East, it hasn't ended well for oil or energy stocks

    Oil hit a multiyear high as the President Trump threatened to strike Syria with missiles, but actual attacks in the Middle East have been bad for the energy sector

  • How 1Q18 Treated Pharmaceutical ETFs
    Market Realist17 days ago

    How 1Q18 Treated Pharmaceutical ETFs

    Pharmaceutical ETFs are securities that are publicly traded on stock markets and designed for investors who don’t have the capacity to hold many stocks but are willing to diversify their investments within the pharmaceutical sector. 

  • Barrons.com17 days ago

    Is Health Care Immune to the Market's Ills?

    While it’s been easy to lose sight of individual sectors amid the market’s recent volatility, there’s been no shortage of health-care news lately, including Incyte’s (INCY) 20% plunge on Friday, after its cancer treatment epacadostat failed in a late-stage trial. Merck (MRK), whose blockbuster drug Keytruda was being tested with epacadostat, bounced back quickly: The shares are higher on Monday, thanks to upbeat data from a lung cancer trial. Meanwhile AbbVie (ABBV) is climbing on news that its rheumatoid arthritis drug showed positive results in a late-stage trial.

  • Which Sector Posted Major Job Gains in March 2018?
    Market Realist17 days ago

    Which Sector Posted Major Job Gains in March 2018?

    The ADP March jobs report was published on April 4, 2018. It offered a deeper insight into employment trends across different sectors in the US employment market. ADP and Moody’s analytics prepare this monthly report.

  • Can HOLX Stock Rebound from Its Recent Lows?
    Market Realist22 days ago

    Can HOLX Stock Rebound from Its Recent Lows?

    Investor Update: Hologic's Recent Partnerships, Product Launches

  • What’s behind Edwards Lifesciences’ Stock Rise?
    Market Realist22 days ago

    What’s behind Edwards Lifesciences’ Stock Rise?

    Recent Developments at Edwards Lifesciences

  • Johnson & Johnson Stock on March 29, 2018
    Market Realist23 days ago

    Johnson & Johnson Stock on March 29, 2018

    Analyzing Johnson & Johnson’s Stock and Valuations in March 2018A look at Johnson & Johnson

  • Discussing BDX’s Recent Stock Price Performance
    Market Realist27 days ago

    Discussing BDX’s Recent Stock Price Performance

    BDX's March 2018 Performance, Recommendations, and Updates

  • What Analysts Recommend for Merck in March 2018
    Market Realist28 days ago

    What Analysts Recommend for Merck in March 2018

    What Analysts Recommend for Merck in March 2018

  • Analysts’ Recommendations for Incyte in March 2018
    Market Realistlast month

    Analysts’ Recommendations for Incyte in March 2018

    Who’s Watching Incyte Corporation in March 2018?

  • How to Invest in Healthcare Stocks the Easy Way
    Motley Foollast month

    How to Invest in Healthcare Stocks the Easy Way

    Here are several smart ways to invest in the companies that keep people healthy.

  • Discussing Teva’s Recent Stock Performance
    Market Realistlast month

    Discussing Teva’s Recent Stock Performance

    On March 20, 2018, Teva Pharmaceutical (TEVA) ended the trading day at a closing price of $17.68. Recently, on February 15, 2018, TEVA stock registered a rise of ~10.5% triggered by the news of an investment of $358 million in the company by Berkshire Hathaway. This news led to the market’s gaining some confidence in the troubled stock, as Berkshire Hathaway investments have been synonymous with value investments.

  • Why the US Workforce’s Quit Rate Has Remained High
    Market Realistlast month

    Why the US Workforce’s Quit Rate Has Remained High

    January’s JOLTS (Job Openings and Labor Turnover Survey) data, which contains information about job openings and total separations, was reported on March 16. The separation total includes layoffs, retirements, and voluntary quits. Total separations in January stood at 5.9 million, representing 4.1% of the total workforce and a minor increase from the December reading of 5.1 million.

  • UnitedHealth Group’s Recent Stock Performance
    Market Realistlast month

    UnitedHealth Group’s Recent Stock Performance

    UnitedHealth Group's Management Changes and Key Developments

  • A Closer Look at Pfizer’s 4Q17 Growth Drivers
    Market Realistlast month

    A Closer Look at Pfizer’s 4Q17 Growth Drivers

    An Overview of Pfizer's 4Q17: What Lies Ahead?

  • Is Stronger Non-Farm Payroll Reducing Fear of a Market Sell-Off?
    Market Realistlast month

    Is Stronger Non-Farm Payroll Reducing Fear of a Market Sell-Off?

    What February Manufacturing Reports Suggest for Developed Markets

  • Analysts’ Recommendations for Gilead Sciences in March
    Market Realist2 months ago

    Analysts’ Recommendations for Gilead Sciences in March

    What Could Drive Gilead Sciences' Valuation in March?

  • Johnson & Johnson’s Valuation in February 2018
    Market Realist2 months ago

    Johnson & Johnson’s Valuation in February 2018

    Changes in Johnson & Johnson's Valuation in February 2018Johnson & Johnson’s valuation

  • Align Technology: Analyst Ratings and Recommendations
    Market Realist2 months ago

    Align Technology: Analyst Ratings and Recommendations

    How Align Technology Is Positioned for 2018: A Post-2017 Analysis

  • Buffett Says Diversification in US Equities Is Best Strategy
    Market Realist2 months ago

    Buffett Says Diversification in US Equities Is Best Strategy

    Key Takeaways from Warren Buffett’s Latest Interview with CNBC